+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Real World Data - Global Strategic Business Report

  • PDF Icon

    Report

  • 180 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6099463
The global market for Real World Data was estimated at US$2.2 Billion in 2024 and is projected to reach US$5.4 Billion by 2030, growing at a CAGR of 15.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Real World Data market.

Global 'Real World Data' Market - Key Trends & Drivers Summarized

Is Real World Data Reshaping The Future Of Evidence-Based Decision Making?

Real World Data (RWD) is becoming a cornerstone of healthcare innovation, shifting the paradigm from controlled clinical trials to evidence drawn from real-life patient experiences. Sourced from electronic health records (EHRs), insurance claims, patient registries, wearables, and mobile health apps, RWD provides insights into treatment efficacy, safety, adherence, and outcomes across diverse populations. It allows regulators, payers, and pharmaceutical companies to understand how therapies perform outside controlled environments, supporting adaptive clinical trials, pharmacovigilance, and value-based reimbursement models. In public health, RWD informs policy decisions and tracks disease progression in real-time. As healthcare systems push for personalized.

What Technologies Are Unlocking The Full Potential Of RWD?

The explosion of health data and advances in data analytics are unlocking new frontiers for Real World Data utilization. Cloud computing, big data platforms, and AI algorithms are enabling the ingestion, harmonization, and real-time analysis of massive, heterogeneous datasets. Natural language processing (NLP) is extracting structured insights from clinical notes and unstructured EHR data. Interoperability frameworks like HL7 FHIR are improving data sharing across systems and stakeholders. Blockchain is being explored to ensure data provenance, security, and patient consent. These technologies are transforming RWD from passive records into dynamic resources that fuel drug development, population health strategies, and personalized treatment pathways. As data ecosystems mature, the quality, reliability, and regulatory acceptance of RWD are also improving.

How Are Stakeholders Across The Healthcare Ecosystem Embracing RWD?

Pharmaceutical companies are integrating RWD into all stages of the drug lifecycle from trial design and site selection to post-market surveillance and label expansion. Regulators like the FDA and EMA are increasingly relying on RWD to support approvals and monitor safety in real-world populations. Payers are using RWD to assess cost-effectiveness and inform coverage decisions. Healthcare providers are applying RWD analytics to improve care coordination, reduce readmissions, and optimize treatment protocols. Patients are also becoming key stakeholders, contributing data through apps and wearable devices while demanding transparency and control. The convergence of stakeholder interests around RWD is fostering partnerships, data consortiums, and innovation hubs that accelerate the transformation of health data into health impact.

What's Accelerating Growth In The Real World Data Market Globally?

The growth in the Real World Data market is driven by advancements in health data infrastructure, regulatory support, and end-user demand for personalized, value-based care. Technologically, improved analytics tools, cloud scalability, and interoperability standards are enabling actionable insights from vast and diverse datasets. From an end-use perspective, biopharma, payers, and health systems are leveraging RWD to drive efficiency, optimize outcomes, and meet evolving care expectations. Increased use of digital health tools, wearables, and patient engagement platforms is generating richer datasets for analysis. Regulatory initiatives supporting RWD in decision-making and policy formulation are also boosting market credibility. As global healthcare systems transition from volume to value, the ability to derive meaningful insights from real-world evidence is becoming a key competitive differentiator.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Services segment, which is expected to reach US$3.7 Billion by 2030 with a CAGR of a 17.7%. The Datasets segment is also set to grow at 12.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $590.5 Million in 2024, and China, forecasted to grow at an impressive 14.9% CAGR to reach $835.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Real World Data Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Real World Data Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Real World Data Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Aetion, Inc., Atropos Health, BEKHealth, Cerner Corporation, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Real World Data market report include:

  • Aetion, Inc.
  • Atropos Health
  • BEKHealth
  • Cerner Corporation
  • Clarify Health Solutions
  • ConcertAI
  • Datavant
  • Evidera, Inc.
  • Flatiron Health, Inc.
  • HealthVerity
  • IBM Corporation
  • ICON plc
  • IQVIA Holdings Inc.
  • K2view
  • Merative
  • Mount Sinai Health System
  • Optum, Inc.
  • Palantir Technologies Inc.
  • PAREXEL International Corporation
  • SAS Institute Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Real World Data - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Accelerated Shift Toward Evidence-Based Healthcare Models Spurs Use of Real World Data
  • Increased Regulatory Acceptance of RWD in Drug Approvals and Label Expansions Drives Market Relevance
  • Rising Use of EHR, Claims, and Patient-Reported Outcomes Data Expands Data Variety
  • Growth in Value-Based Care and Health Economics Research Strengthens Demand for Real-World Evidence
  • AI and Advanced Analytics Integration Enhances Data Utility in Clinical and Commercial Strategy
  • Collaborations Between Pharma, Payers, and Tech Firms Propel RWD Platform Development
  • Decentralized Clinical Trials and Virtual Health Models Expand Demand for Real-Time Patient Data
  • Regulatory Pressure for Post-Market Surveillance and Pharmacovigilance Supports Adoption
  • Privacy Concerns and Data Governance Requirements Present Compliance Challenges
  • Global Expansion of Health Data Infrastructure Opens Regional Growth Opportunities
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Real World Data Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Real World Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Real World Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Datasets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Datasets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Government Agencies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Government Agencies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Pharmaceutical & Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Drug Development & Approvals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Drug Development & Approvals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Market Access & Reimbursement / Coverage Decisions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Market Access & Reimbursement / Coverage Decisions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Post-Market Surveillance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Post-Market Surveillance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 28: USA Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 30: USA Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: USA 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
CANADA
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 36: Canada Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Canada 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
JAPAN
  • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 42: Japan Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Japan 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
CHINA
  • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 46: China Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 48: China Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: China 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
EUROPE
  • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Real World Data by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Real World Data by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 58: Europe Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Europe 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
FRANCE
  • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 60: France Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 64: France Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: France 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
GERMANY
  • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 70: Germany Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Germany 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
ITALY
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 76: Italy Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Italy 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
UNITED KINGDOM
  • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 78: UK Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 82: UK Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: UK 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
REST OF EUROPE
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Rest of Europe 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
ASIA-PACIFIC
  • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Asia-Pacific 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
REST OF WORLD
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
  • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 101: Rest of World 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aetion, Inc.
  • Atropos Health
  • BEKHealth
  • Cerner Corporation
  • Clarify Health Solutions
  • ConcertAI
  • Datavant
  • Evidera, Inc.
  • Flatiron Health, Inc.
  • HealthVerity
  • IBM Corporation
  • ICON plc
  • IQVIA Holdings Inc.
  • K2view
  • Merative
  • Mount Sinai Health System
  • Optum, Inc.
  • Palantir Technologies Inc.
  • PAREXEL International Corporation
  • SAS Institute Inc.

Table Information